OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Monk on Remaining Unmet Needs in Recurrent Ovarian Cancer

January 3rd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

January 3rd 2022

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Dr. Kremyanskaya on the Next Steps of the MANIFEST Trial in Myelofibrosis

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Jain on the Push Toward Personalized Treatment Approaches in CRC With Liver Metastases

January 3rd 2022

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

January 3rd 2022

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLL

January 3rd 2022

Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.

Dr. Ratan on the Steps of Diagnosing Desmoid Tumors

January 3rd 2022

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

December 23rd 2021

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

Dr. Sherbenou on Future Directions With Maintenance Therapy in Multiple Myeloma

December 23rd 2021

Daniel Sherbenou, MD, PhD, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Dr. Spaggiari on the Potential Utility of Liver Transplantation in CRC With Liver Metastases

December 23rd 2021

Mario Spaggiari, MD, discusses the potential utility of liver transplantation as a treatment option for patients with colorectal cancer liver metastases.

Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

December 23rd 2021

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Dr. Banerjee on the Rationale to Create a Supportive Mobile Health App for CAR T-Cell Therapy

December 23rd 2021

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers to use throughout the therapeutic process.

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

December 23rd 2021

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Dr. Bekaii-Saab on the Benefits Derived With Bevacizumab Plus TAS-102 in mCRC

December 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC

December 22nd 2021

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Dr. Riedell on an Analysis Evaluating the Effect of Time to Relapse on OS in MCL

December 22nd 2021

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Dr. Rimawi on the Clinical Implications of the FeDeriCa Trial in Early-Stage HER2+ Breast Cancer

December 22nd 2021

Mothaffar Fahed Rimawi, MD, discusses the clinical implications of the phase 3 FeDeriCa trial in early-stage, HER2-positive breast cancer.

Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL

December 22nd 2021

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Zurita-Saavedra on Emerging Frontline Therapies in Metastatic HSPC

December 22nd 2021

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

December 22nd 2021

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.